Avanir Pharmaceuticals’ AVP 13358 for Asthma
May 3, 2004 by admin · Leave a Comment
On May 3, 2004 Avanir Pharmaceuticals released results of its Phase I clinical trial with AVP 13358 for asthma. The company reported that this trial, involving 54 healthy volunteers, was designed to demonstrate the safety, tolerability, and pharmacokinetic profile of a single oral administration of AVP 13358. The company indicated that AVP 13358 was well [...]
Zenapax (daclizumab)
March 19, 2004 by admin · Leave a Comment
On March 15, 2004 Protein Design Labs, Inc. reported results from the initial clinical study of the humanized antibody daclizumab in patients with chronic, persistent asthma whose disease was not well controlled with high doses of inhaled corticosteroid therapy. This Phase II randomized, double-blind, placebo-controlled clinical trial was conducted at 24 centers in the United [...]
Daxas (roflumilast)
March 12, 2004 by admin · Leave a Comment
On March 12, 2004 Altana AG announced that it had presented strong data on its Chronic Obstructive Pulmonary Disease (COPD) drug roflumilast, also known as Daxas, at a German scientific meeting. Daxas, which is to be jointly marketed with Pfizer, has been filed for marketing approvals in Europe. Altana has said it hopes Pfizer will [...]